Discussing Breast Cancer ASCO 2023 Highlights
Focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies
August 23, 2024
Key Points
NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients
SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients
X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer
Tags:
Related Posts
AlgorithmsNET2025October 02, 2025
Exploring the role of targeted radiopharmaceutical treatment in NETs
AlgorithmsMelanoma2025September 25, 2025